This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
The editorial by Dr. Langer-Gould1 included misleading statements about teriflunomide. Human data for teriflunomide are available. Teriflunomide is the active metabolite of leflunomide. Animal studies demonstrated a risk of teratogenicity for both. However, a prospective trial of leflunomide,2 confirmed by over 2.3 million patient-years of postmarketing exposure, showed no increased risk for major birth defects, major or minor anomalies, or spontaneous abortions. Similarly, in the teriflunomide clinical program (greater than 12 years and greater than …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Alert Me
Recommended articles
A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses
Pregnancy decision-making in women with multiple sclerosis treated with natalizumab
Induction of gut regulatory CD39+ T cells by teriflunomide protects against EAE
Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis